NIKKEI 225
38,054.13 -502.74 (-1.30%) HANG SENG
18,230.19 -246.82 (-1.34%) CRUDE OIL
77.71 -1.52 (-1.92%) GOLD FUTURES
2,366.10 +2.00 (+0.08%) DOW
38,154.35 -287.19 (-0.75%) Bitcoin GBP
54,413.28 +1,432.45 (+2.70%)
Clearside Biomedical, Inc. (CLSD)
| Previous close | 1.3500 |
| Open | 1.3800 |
| Bid | 1.3700 x 100 |
| Ask | 1.4000 x 100 |
| Day's range | 1.3591 - 1.4400 |
| 52-week range | 0.6500 - 2.1200 |
| Volume | |
| Avg. volume | 390,874 |
| Market cap | 103.503M |
| Beta (5Y monthly) | 2.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5500 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.33 |
GlobeNewswireClearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics - ALPHARETTA, Ga., May 21, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprac
- Thomson Reuters StreetEvents
Q1 2024 Clearside Biomedical Inc Earnings Call
Q1 2024 Clearside Biomedical Inc Earnings Call
Insider MonkeyClearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call Transcript May 9, 2024 Clearside Biomedical, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the Clearside Biomedical First Quarter 2024 Financial Results and Corporate Update Conference Call. […]
